FDA Approves New Drug for Treatment of Seizures Associated With Dravet Syndrome – Drug for nerve pain boosts high for opioid abusers.

29960_pharmacyboard_standard_081816Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Approves New Drug for Treatment of Seizures Associated With Dravet Syndrome – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA approved have approved stiripentol (Diacomit) for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy.1 Stiripentol is indicated for use in patients 2 years of age and older who are taking clobazam.1 There are no clinical data to support the use of stiripentol as monotherapy in Dravet syndrome, according to the FDA.

Dravet syndrome is a rare genetic condition that usually appears during the first year of life with prolonged fever-related seizures. Other types of seizures typically appear later, including myoclonic seizures. Additionally, status epilepticus, a potentially life-threatening state of continuous seizure activity requiring emergency medical care, may occur. Children with Dravet syndrome typically experience poor development of language and motor skills, hyperactivity, and difficulty relating to others.1

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.